Research center
What the evidence actually says about peptides
1213 entries. Filter by evidence type, peptide, or outcome.
Showing 48 of 1057 entries
- Human
on Tirzepatide
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Okuma H. · Diabetology international
Background Tirzepatide improves body weight and glycemic control in patients with type 2 diabetes, but factors associated with inter-individual differences after switching remain unclear.
Read on DOI → - Human
RCT · Ongoing · on Testagen
Product Transference Study of Testagen™ TDS®-Testosterone
ClinicalTrials.gov
This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.
View trial → - Human
RCT · Ongoing · on Semaglutide
Semaglutide for the Treatment of Cannabis Use Disorder
ClinicalTrials.gov
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1. Does semaglutide effect reactivity to cannabis-related cues? 2.
View trial → - Human
on Oxytocin
Salivary oxytocin and testosterone in empathic stress responding: a pilot study
Heilmann K, Walter M, Engert V. · Stress (Amsterdam, Netherlands)
Suffering the stress of others (termed empathic stress or stress contagion) may affect an individual's health and well-being.
Read on DOI → - Human
Cohort · Ongoing · on MOTS-c
Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding
ClinicalTrials.gov
This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed.
View trial → - Human
on MGF
Multimodal graph-based fusion via image descriptions for few-shot open-set recognition
Huang X, Choi SH. · Neural networks : the official journal of the International Neural Network Society
Few-shot open-set recognition (FSOR) presents unique challenges due to the limited labeled samples and the presence of unknown classes during inference.
Read on DOI → - Human
on Kisspeptin-10
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche
Banerjee AA, Bhanarkar SR, Kashikar S, Keshwani R, Walia S, Kavya DR, Bombe S, Pande S, Modi DN, Pathak BR, Joshi B, Tandon D, Patil A, Begum S, Mahale SD, Rao S, Surve SV. · Clinica chimica acta; international journal of clinical chemistry
Background Distinguishing idiopathic central precocious puberty (ICPP) from premature thelarche (PT) remains a clinical challenge and often necessitates GnRH stimulation testing.
Read on DOI → - Human
Review · on Glutathione
AA-Induced Lipid Peroxidation at the Center of Tumor Cell Apoptosis and Ferroptosis
Das UN. · Reviews of physiology, biochemistry and pharmacology
Polyunsaturated fatty acids (PUFAs), especially gamma-linolenic acid (GLA), arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), can block HMG-CoA reductase activity and thus decrease cholesterol synthesis/formation.
Read on DOI → - Human
RCT · Ongoing · on GHK-Cu
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
ClinicalTrials.gov
The goal of this clinical trial is to investigate GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults, and to investigate the efficacy of X39 patch on GHK and GHK-Cu blood levels in healthy adults compared to a placebo.
View trial → - Human
RCT · Ongoing · on BPC-157
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
ClinicalTrials.gov
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR).
View trial → - Human
RCT · 2026 · on hCG
Device for Treating Generalized Anxiety
ClinicalTrials.gov
The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD).
View trial → Case report · 2026 · on hCG
Choriocarcinoma at an Abdominal Wall Cesarean Scar: Recurrence After Multi-Line Chemotherapy and Exploration of Salvage Therapy
Xu S, Huang C, Wang M, Wu W, Zhou J. · International journal of women's health
Choriocarcinoma arising at an abdominal wall cesarean scar is not only exceedingly rare and diagnostically challenging but also represents a therapeutic dilemma, particularly when it becomes chemoresistant or relapses after multi-line chemotherapy.
Read on DOI →2026 · on hCG
Optimization of Pregnancy Testing in the Emergency Department: A Quality Improvement Initiative
Holstege M, Mukubwa N, Smith M, Layng T, Wendel S. · American journal of medical quality : the official journal of the American College of Medical Quality
Background At our institution, a review of emergency department pregnancy testing identified excess use of serum quantitative (quant) human chorionic gonadotropin (hCG) when only a binary result was clinically indicated. Additionally, we observed delays in point-of-care (POCT) urine hCG turnaround time.
Read on DOI →2026 · on hCG
Serum Beta-Human Chorionic Gonadotropin (β-hCG) Trends and Their Association With Abdominal Wound Healing After Cesarean Section: An Observational Study
Vishwakarma A, Kaithwas K, Chaubey L, Singh M, Singh AP, Singh TB. · Cureus
Background and objective Beta-human chorionic gonadotropin (β-hCG) is an established biomarker in pregnancy assessment and in the management of trophoblastic and germ cell disorders.
Read on DOI →2026 · on hCG
Evaluation and performance of the β-hCG discriminatory zone and targeted ultrasound findings for early pregnancy diagnosis in a high-risk population: a retrospective cohort study at a US safety-net hospital
Cherouveim P, Tuli S, Cetin E, Garner J, Fayyaz T, Soylu M, Lachance J, Merida Reyes MA, Kobold R, Akinpeloye A. · BMJ open
Read on DOI →- Human
2026 · on hCG
Nonlinear relationship between serum LH levels on hCG trigger day and live birth rates in patients with fresh embryo transfer: a retrospective cohort study
Zhang Y, Xiao Y, Yang A, Yang Y, Jiang L, Zheng J, Guo K, Wang W. · Frontiers in endocrinology
Background In assisted reproductive technology (ART), the assessment of sex hormones is indispensable. Maintaining an appropriate level of luteinizing hormone (LH) is crucial for ovarian and endometrial development.
Read on DOI → 2026 · on hCG
Relationship Between Dominant Follicle Diameter on the hCG Trigger Day and Live Birth After Modified Natural Cycle Frozen Embryo Transfer: A Retrospective Cohort Study
Huang C, Jiang Y, Liu J, Zhu Y, Zhang H, Jiang R, He F, Xing J. · International journal of general medicine
Background The impact of dominant follicular diameter at hCG trigger on live birth rate (LBR) in modified natural cycle frozen-thawed embryo transfer (mNC-FET) remains unclear. This study aimed to evaluate this relationship and explore whether flexible triggering based on follicle size is acceptable.
Read on DOI →2026 · on hCG
Reference ranges for early pregnancy hCG following embryo transfer: A cohort study of 4807 embryo transfer cycles leading to live birth at term
Hofer N, Moykens M, Cools W, Roelens C, Mackens S. · Fertility and sterility
Objective To establish gestational day-specific reference values for serum hCG in early pregnancy following embryo transfer and identify maternal and treatment-related factors contributing to its variability. Design Retrospective, single-center cohort study.
Read on DOI →2026 · on Vilon
Secondary-Amine Relay Enables Lysine-Directed Multicomponent Functionalization of Peptides
Ren C, Zhang M, Jiang T, Wan F, Lv Y, Yang L, Li C. · JACS Au
Multicomponent reactions provide powerful modularity for peptide functionalization, but their application to lysine residues remains limited by the low efficiency of direct primary-amine-based activation pathways under peptide-compatible conditions.
Read on DOI →- Human
Review · 2026 · on Vilon
Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence
Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, Lee W, Sayed D, Amirdelfan K, Robinson CL. · International journal of molecular sciences
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a chemically distinct pineal-derived polypeptide preparation.
Read on DOI → - Human
RCT · 2026 · on Vasoactive Intestinal Peptide (VIP)
Acupuncture for Postoperative Gastric Emptying Delay
ClinicalTrials.gov
This multicenter clinical trial, conducted at Qilu Hospital of Shandong University and collaborating institutions, prospectively assesses the efficacy and safety of acupuncture for postoperative delayed gastric emptying.
View trial → - Human
Case report · 2026 · on Vasoactive Intestinal Peptide (VIP)
Vasoactive Intestinal Peptide (VIP)-Secreting Neuroblastic Tumors in Children Presenting With Chronic Secretory Diarrhea: A Report of Two Cases
Barbar M, Sultan I, Alrifaai A, Al-Dabbagh A, Halalsheh H. · Cureus
Vasoactive intestinal peptide (VIP)-secreting neuroblastic tumors are rare pediatric neoplasms that may present with chronic secretory diarrhea prior to tumor detection, posing significant diagnostic and therapeutic challenges.
Read on DOI → - Human
Review · 2026 · on Tirzepatide + Retatrutide
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione F, Loomba R. · Cell reports. Medicine
Recent therapeutic advances have resulted in US Food and Drug Administration (FDA) approval of the first pharmacological agents-resmetirom and semaglutide-for advanced metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis, reshaping the therapeutic landscape of the disease.
Read on DOI → - Human
Review · 2026 · on Tirzepatide + Retatrutide
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Gupta M, Shukla J. · The Indian journal of medical research
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Read on DOI → Review · 2026 · on Tirzepatide + Retatrutide
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Puspitasari IM, Putra DS, Deliyana AN, Adiputri NI, Octovia LI, Paramita SA, Sinuraya RK. · Diabetes, metabolic syndrome and obesity : targets and therapy
Obesity remains a major global public health challenge associated with increased morbidity, mortality, and reduced quality of life, necessitating effective treatment strategies beyond lifestyle modifications.
Read on DOI →2026 · on Tirzepatide + Retatrutide
Beyond weight loss: Preserving muscle health in the incretin era
Imaizumi T, Yabe D. · Journal of diabetes investigation
Read on DOI →- Human
2026 · on Tirzepatide + Retatrutide
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM, Sia JE, Rahman OU, Ahmad M, Shahid N, Gardezi SA, Joseph KV, Behary Paray N, Zulfiqar E. · Cardiology in review
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
Read on DOI → - Human
Meta-analysis · 2026 · on Tirzepatide + Retatrutide
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis
Amjad MM, Khan MM, Sarwar F, Ali A, Ali M, Bakhash F, Abid H, Ibrahim F, Mustafa K, Ali DE, Fayyaz MMN, Hassan H, Mian SM, Yaseen M, Qamar I, Khan AH, Ullah S, Khan BW. · Diabetes, obesity & metabolism
Background Dual glucagon-like peptide-1/glucagon receptor (GLP-1/GCGR) agonists represent a novel obesity treatment class, but existing meta-analyses often conflate them with GIP-containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class-specific efficacy and safety incompletel…
Read on DOI → - Human
RCT · 2026 · on Tirzepatide
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
ClinicalTrials.gov
Acute ischemic stroke caused by blockage of a large artery in the brain is one of the leading causes of death and long-term disability worldwide.
View trial → - Human
RCT · 2026 · on Tirzepatide
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
ClinicalTrials.gov
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide.
View trial → - Human
2026 · on Tirzepatide
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
He Y, Ma T, Xing H, Cao X, Song F, Pan Y, Ren L. · European journal of pharmacology
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.
Read on DOI → - Human
Cohort · 2026 · on Tirzepatide
Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty
Davis SC, Patel SV, Fletcher S, McLaughlin JP, Deren ME, Piuzzi NS. · European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
Purpose Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, whereas semaglutide is selective for the GLP-1 receptor.
Read on DOI → - Animal
2026 · on Tirzepatide
Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice
Macêdo APA, da Conceição de Mattis LR, de Lima RD, Barbosa LA, Pinotti CB, Brisque GD, Dias LM, Pitoli BS, Avelino AA, Antonio GCF, Muñoz VR, Antunes GC, Figueiredo LS, Cintra DE, et al. · The Journal of physiology
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors with potent effects on body weight regulation, glucose homeostasis and metabolic health.
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort
Rescalli MB, Fagiolini A, Carmellini P, Pinzi M, Castaldo F, Cuomo A. · Human psychopharmacology
Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.
Read on DOI → 2026 · on Tirzepatide
Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany
Füchtenbusch M, Kraus M, Heitmann E, Wilhelm S, Schwarz L, Bendel J, Hennies N. · Advances in therapy
Introduction This study describes real-world characteristics and utilisation patterns of tirzepatide among adults with type 2 diabetes in German office-based practice. Methods This retrospective observational study analysed data from the CompuGroup Medical Healthcare Database.
Read on DOI →- Human
2026 · on Tirzepatide
Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide
Aminian A, Hammad AF, Sadeghmousavi S, Daftari G, Ferguson L, Tu C, Gasoyan H, Nissen SE. · Annals of surgery
Objective To evaluate 2-year weight loss after bariatric surgery among adults with intolerable adverse effects or inadequate weight loss with semaglutide or tirzepatide.
Read on DOI → - Human
Case report · 2026 · on Tirzepatide
Tirzepatide-associated severe euvolemic hyponatremia with syndrome of inappropriate antidiuretic hormone secretion-compatible biochemical features
Prasad NT. · Indian journal of pharmacology
Abstract Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that is being increasingly used for the management of type 2 diabetes mellitus and obesity.
Read on DOI → - Human
Cohort · 2026 · on Tirzepatide
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Arslan T. · Endocrine
Background Semaglutide and tirzepatide are widely used for type 2 diabetes and obesity, but comparative post-marketing safety data remain limited.
Read on DOI → - Human
2026 · on Tirzepatide
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
Tudi K, Jie Z, Chen Z, Liao W, Liu Y, Tang G. · Molecular pharmaceutics
Tirzepatide is a clinical dual GLP-1R and GIPR agonist for type 2 diabetes and obesity, and non-invasive approaches to assess its in vivo biodistribution and systemic toxicity in living animals remain limited.
Read on DOI → - Human
Cohort · 2026 · on Tirzepatide
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
Manueli Laos EG, Fontaine-Nicola A, Serafica B, Zhang L, Layden BT, Berger R, Orda CA, Schlottmann F, Pirzada A, Masrur MA. · Clinical obesity
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Read on DOI → Review · 2026 · on Thymulin
Nano zinc supplementation in broiler nutrition: current evidence, mechanisms of action, and future perspectives
Rodriguez Velazquez D, Hosseintabar-Ghasemabad B, Varela Guerrero JA, Gorlov IF, Slozhenkina MI, Mosolov AA, Ondrašovičová S, Seidavi A, García Martínez JE, Rodríguez Huerta FA, Kr, et al. · Frontiers in veterinary science
Zinc is an essential trace mineral involved in numerous biological processes, including growth, antioxidant defense, immune function, and intestinal integrity in broiler chickens. Optimizing its bioavailability remains an important objective in modern poultry nutrition.
Read on DOI →- Human
Review · 2026 · on Thymulin
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS. · Biomedicines
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
Read on DOI → - Human
2026 · on Thymulin
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy
Kanemaru H, Luong S, Yamamoto Y, Mizukami Y, Ito F. · Nature communications
Chronic inflammation increases with age and contributes to cancer progression and therapeutic resistance, yet the mechanisms underlying this process remain incompletely understood.
Read on DOI → - Animal
2026 · on Thymosin Alpha-1 + Thymulin
Zinc Coordination by Thymosin β4: Structural Determinants and Functional Implications
Lachowicz JI, Congiu T, Salis A, Cesare Marincola F. · International journal of molecular sciences
Thymosin β4 (Tβ4) is a highly acidic, intrinsically disordered 43-amino-acid peptide with diverse biological functions, yet its interactions with metal ions remain poorly understood.
Read on DOI → - Human
2026 · on Thymosin Alpha-1
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1
Li T, Wu BL, Yu CL, Jin LY. · Clinical case reports
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
Read on DOI → - Human
2026 · on Thymosin Alpha-1
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Wei Y, Chen J, Zhang Y, Liu Y, Zhu F, Wang X, Zhou X, Wu C, Zhang W, Chen J, Zhang Y, Pan N, Chen K, Zheng S, Yan C, Liu L, Wang L. · Cancer research
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (AB) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of coadministered or second-line immunotherapies.
Read on DOI → - Human
Review · 2026 · on Thymosin Alpha-1
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review
Kim SD, Kim KR, Kim DH, Yeo T, Choi MJ, Park SJ, Yoo HS. · Pharmaceuticals (Basel, Switzerland)
Background : Thymosin alpha 1 (Tα1, thymalfasin) is a thymus-derived immunomodulatory peptide investigated as an adjunctive therapy in cancer care. Although studied across malignancies, its evidence landscape has not been systematically mapped.
Read on DOI → - Human
2026 · on Thymosin Alpha-1
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis
Kang X, Wang S, Zhang L, Hu M, Su X, Liu Y, Qin Q, Yi H, Yuan L, Cai W, Wei L, Lu Z. · Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Communication between the immune system and the brain is critical for neuronal health, yet the molecular signals that mediate this crosstalk are not fully understood. Here, we uncover an unexpected and direct neuroprotective axis linking the thymus to the central nervous system (CNS).
Read on DOI →